Axsome reports preliminary 4Q and FY 2025 net product revenue of $196M and $638.5M, up 65% and 66% YoY

Axsome Therapeutics, Inc.

2025-FY EPS reported -$3.68 revenue$638,496,000

Total preliminary 4Q net product revenue $196.0M (+65% YoY); full year $638.5M (+66% YoY).
AUVELITY net product sales: $155.1M (4Q), $507.1M (FY).
SUNOSI net product revenue: $36.7M (4Q), $124.8M (FY).
SYMBRAVO net product sales (launched June 2025): $4.1M (4Q), $6.6M (FY).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.